PARSACLISIB: 74 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
74
Total FAERS Reports
7 (9.5%)
Deaths Reported
39
Hospitalizations
74
As Primary/Secondary Suspect
1
Life-Threatening
9
Disabilities
First Report: 20161113 · Latest Report: 20240903
What Are the Most Common PARSACLISIB Side Effects?
#1 Most Reported
Off label use
23 reports (31.1%)
#2 Most Reported
Disease progression
15 reports (20.3%)
#3 Most Reported
Pyrexia
14 reports (18.9%)
All PARSACLISIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 23 | 31.1% | 1 | 8 |
| Disease progression | 15 | 20.3% | 1 | 1 |
| Pyrexia | 14 | 18.9% | 0 | 10 |
| Pneumonia | 11 | 14.9% | 0 | 9 |
| Bronchitis | 9 | 12.2% | 0 | 9 |
| Neutropenic sepsis | 9 | 12.2% | 0 | 9 |
| Neutrophil count decreased | 9 | 12.2% | 0 | 9 |
| Blood lactate dehydrogenase increased | 8 | 10.8% | 0 | 1 |
| Neutropenia | 8 | 10.8% | 1 | 2 |
| Hypokalaemia | 7 | 9.5% | 0 | 7 |
| Enterococcal bacteraemia | 6 | 8.1% | 0 | 0 |
| Intentional product use issue | 6 | 8.1% | 0 | 6 |
| Thrombocytopenia | 6 | 8.1% | 0 | 0 |
| Acute kidney injury | 5 | 6.8% | 1 | 4 |
| Alanine aminotransferase increased | 5 | 6.8% | 1 | 0 |
| Aspartate aminotransferase increased | 5 | 6.8% | 1 | 0 |
| Atrial fibrillation | 5 | 6.8% | 1 | 2 |
| Electrocardiogram qt prolonged | 5 | 6.8% | 0 | 5 |
| Hypertensive cardiomyopathy | 5 | 6.8% | 0 | 5 |
| Hypomagnesaemia | 5 | 6.8% | 0 | 5 |
Who Reports PARSACLISIB Side Effects? Age & Gender Data
Gender: 31.2% female, 68.8% male. Average age: 66.6 years. Most reports from: US. View detailed demographics →
Is PARSACLISIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2016 | 3 | 0 | 3 |
| 2017 | 11 | 0 | 10 |
| 2018 | 6 | 0 | 6 |
| 2019 | 4 | 0 | 2 |
| 2020 | 12 | 0 | 12 |
| 2022 | 5 | 2 | 5 |
| 2023 | 1 | 0 | 0 |
| 2024 | 1 | 0 | 1 |
What Is PARSACLISIB Used For?
| Indication | Reports |
|---|---|
| Diffuse large b-cell lymphoma | 24 |
| Mantle cell lymphoma | 11 |
| Follicular lymphoma | 7 |
| B-cell lymphoma | 6 |
| Product used for unknown indication | 5 |
Official FDA Label for PARSACLISIB
Official prescribing information from the FDA-approved drug label.